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The C-peptide links the insulin A and B chains in proin-
sulin, providing thereby a means to promote their efﬁcient
folding and assembly in the endoplasmic reticulum dur-
ing insulin biosynthesis. It then facilitates the intracellular
transport, sorting, and proteolytic processing of proinsulin
into biologically active insulin in the maturing secretory
granulesoftheβ cells.Thesemanifoldfunctionsimposesig-
niﬁcantconstraintsontheC-peptidestructurethatarecon-
served in evolution. After cleavage of proinsulin, the intact
C-peptide is stored with insulin in the soluble phase of the
secretory granules and is subsequently released in equimo-
lar amounts with insulin, providing a useful independent
indicator of insulin secretion. This brief review highlights
many aspects of its roles in biosynthesis, as a prelude to
consideration of its possible additional role(s) as a physio-
logically active peptide after its release with insulin into the
circulation in vivo.
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INTRODUCTION
Intracellular cleavage of protein and polypeptide precursors
is now recognized as a widely occurring biosynthetic mecha-
nism that can play many important roles in preparing biologi-
callyimportantmoleculesfortheirfunction.Proinsulinwasthe
ﬁrst precursor protein of this type to be identiﬁed, sequenced,
and shown to precede insulin in appropriately designed pulse-
chase biosynthetic labeling experiments (Steiner et al., 1969).
In insulin biosynthesis, it fulﬁlls the important biologic role of
facilitating the formation of the correct secondary and tertiary
structure of the hormone. Once this function has been accom-
plished at the level of the rough endoplasmic reticulum (RER),
newly formed proinsulin moves within minutes to the Golgi re-
gionoftheβ cell,whereitsproteolyticprocessingtoinsulinand
C-peptide is initiated. The sequestration of this process within
the trans-Golgi network (TGN) and immature secretory gran-
ules results in the retention of both the C-peptide and insulin
in the storage granules in equal amounts, and both peptides are
then released together into the circulation during active secre-
tion(exocytosis)(Steineretal.,2000a).Thesearethetwomajor
secreted products of the β cell, but the secretory granules also
contain a variety of other peptides, including small amounts
of proinsulin and some intermediates of proinsulin processing,
islet amyloid polypeptide (IAPP, aka amylin), chromogranins,
and many other minor components of possible functional sig-
niﬁcance (Nishi et al., 1990).
THE C-PEPTIDE RIA AND ITS CLINICAL
APPLICATION
Because of the secretion of insulin and C-peptide in
nearly equimolar amounts, measurements of immunoreactive
C-peptide release has proven to be highly useful as an inde-
pendent measure of insulin secretory rate in vivo in humans,
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FIGURE 1
Amino acid sequences of proinsulin C-peptides from selected vertebrates and a mollusc, Lymnae stagnalis (for sources see
Steiner, 1984; Smit, 1996; Chan, 1990).
especially in diabetic subjects receiving exogenous insulin in-
jections (Rubenstein et al., 1969; Polonsky et al., 1986). Al-
thoughsomeintragranularprocessingofratC-peptidehasbeen
reported (Verchere et al., 1996), the C-peptide in man does not
undergo signiﬁcant further processing prior to its release and
also is quite stable in the circulation, exhibiting a very slow
turnover rate (>30 minutes) (Polonsky et al., 1986; Verchere
et al., 1996). This metabolic behavior contrasts with the rapid
removal of insulin from the circulation via insulin receptor–
mediated uptake followed by lysosomal degradation (Steiner
et al., 2000b; Polonsky and O’Meara, 2001). The half-life
of insulin is therefore much shorter than that of C-peptide—
approximately 3.0 minutes or less under normal conditions.
These large differences in metabolic clearance must be taken
into account in translating C-peptide values into insulin se-
cretory rates in vivo. Excellent methods for deconvolution of
C-peptide values have been developed by Polonsky and
O’Meara (2001) and have enabled the widespread use of
serum/plasma C-peptide assays for evaluating β-cell reserve
in both diabetic and normal subjects.
C-PEPTIDE STRUCTURE
The mammalian proinsulin C-peptide is typically 31 amino
acidsinlengthandcontains4or5acidicresiduesand,inonlya
few species, a single basic residue (Figure 1). It is highly vari-
able in structure, but generally is devoid of aromatic amino
acids. Although many studies have failed to detect ordered
structures in the C-peptide (Weiss et al., 1990), more recent
equilibrium denaturation studies have indicated that it is not
a random coil, but rather contains detectable ordered structure
bothwhenfreeorattachedtoinsulininproinsulin(Bremsetal.,
1990). Moreover, the presence of the C-peptide in proinsulin
inﬂuences insulin core packing evidently through the forma-
tion of some kind of local stable structure at the C-A junction
(Weiss et al., 1990). The central region of the C-peptide usu-
ally contains a glycine-rich segment that would be expected to
confer great ﬂexibility, allowing it to bend back upon itself to
form a U-shaped or hairpin structure when attached to the in-
sulin chains in native proinsulin where the C-terminus of the
B chain domain and the N-terminus of the A chain domain are
only 8 to 10 ˚ A apart, based on x-ray analysis of crystalline in-
sulin (Blundell et al., 1972). The shortest known mammalian
C-peptide is 26 amino acids in length, as in bovine proinsulin
(Nolan et al., 1971). A length of about 30 residues is a highly
conserved feature even in the proinsulin-like peptides found in
many invertebrates (including molluscs and arthropods) (Smit
etal.,1996;Lagueuxetal.,1990;Kondoetal.,1996),butnotin
nematodessuchasCaenorhabditiselegans(Duretetal.,1998).
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23–amino acid peptide (Peterson et al., 1972), but this turned
out to be only a fragment of a typical 31–amino acid C-peptide
that is encoded in the dog insulin gene (Kwok et al., 1983).
The reason for this is that the dog C-peptide contains one of
those rarely occurring basic residues, an arginine at position
8 (Figure 1), which evidently is processed by one of the pro-
hormone convertases during the conversion of dog proinsulin
to insulin. This results in storage of the N-terminally truncated
23-residue C-peptide in the pancreatic islets. Whether the N-
terminal octapeptide is also stored and released with the other
products during secretion has not been examined, but seems
quite likely to be the case. However, it would probably lack the
C-terminal arginine moiety (see below).
MECHANISM OF PROCESSING
OF PROINSULIN
Theconversionofproinsulintoinsulin,liketheprocessingof
manyotherneuroendocrineprecursors,occursthroughthecom-
bined action of the prohormone convertases PC2 and PC1/3.
These are serine endoproteases having a high degree of speci-
ﬁcityforcleavageafterpairedbasicaminoacidsequences,such
asLys-ArgorArg-Arg(Zhouetal.,1999;MullerandLindberg,
1999; Seidah and Chr´ etien, 1999). Their action is followed by
that of carboxypeptidase-E (CPE), a carboxypeptidase-B–like
enzyme having a high speciﬁcity for C-terminal basic residues
(Fricker et al., 1986). The latter enzyme(s) removes the C-
terminal basic amino acids exposed by the endoproteases, re-
sulting in the generation of native insulin and C-peptide free of
any linking basic residues. Without CPE, the buildup of such
extendedintermediateproducts(insulin-Arg-ArgorC-peptide-
Lys-Arg) inhibits the action of the convertases, resulting in in-
completeprocessingofprecursors(Dayetal.,1998).Disruption
or inactivating mutations of the genes encoding PC2, PC1/3, or
CPEallleadtomarkeddefectsinproinsulinprocessinginmice
(Furuta et al., 1998; Zhu et al., 2002; Naggert et al., 1995).
Undernormalconditions,theprocessingofproinsulininthe
secretorygranulesishighlyefﬁcient,yieldingover95%insulin
and C-peptide, with only small amounts of residual proinsulin
and intermediates (Steiner et al., 2000a). However, in the pres-
ence of β-cell stress, as in untreated type 1 or type 2 diabetes,
processingofproinsulinmaybelesscompleteandthisdefectis
then magniﬁed in the circulation due to the signiﬁcantly slower
clearance of proinsulin (resulting mainly from its reduced
receptor afﬁnity), sometimes leading to highly elevated circu-
lating proinsulin levels. The basis of this defect in the diabetic
remainsunclear,butprobablyarisesfromacombinationoffac-
tors, including impaired granule retention and/or acidiﬁcation
and reduced expression of convertases (Rhodes and Alarc´ on,
1994).
EVOLUTIONARY ASPECTS OF INSULIN
AND C-PEPTIDE
Although it is now clear that 2-chain insulin molecules
are found very widely in the animal kingdom, other insulin-
related proteins also exist in many species. Among these are
the two closely related insulin-like growth factors, IGFs 1 and
2. These extended single-chain molecules have been found so
faronlyinvertebrates(LeRoithandRoberts,1993).Theyshare
similaritiesbothinstructureandactiontoinsulin,exertingtheir
effects via the homologous IGF1 receptor, which is also a het-
erotetrameric tyrosine kinase family member like the insulin
receptor (De Meyts and Whittaker, 2002). Their divergence
from a common insulin-like ancestor early in the course of ver-
tebrate evolution (Chan et al., 1990) appears to have assisted
the partition of growth regulation (IGFs) from metabolic regu-
lation (insulin), although with some functional overlap due to
the mutual interdependence of these processes and also a low
levelofreceptorcross-talk.Ininvertebrates,classicinsulin-like
peptidesoftenregulatebothactivitiesorhaveamoreprominent
role in growth control (Brogiolo et al., 2001).
The uncleaved integral C-domains in IGFs 1 and 2 are con-
siderably shorter than the C-peptide in proinsulin and also ap-
pear to contribute to receptor binding (Cara et al., 1990). The
A chain domains are also extended variably through a short D
domain and a longer E domain. The latter domain is removed
during processing of the IGFs by furin and/or other members
of the prohormone convertase family during their constitutive
secretionfromawidevarietyofcellsinthebody(Duguayetal.,
1997, 1998). The shorter C domain in these insulin-like forms
suggests that overall length in the proinsulin C-peptides may
be a required feature for successful processing of proinsulin to
insulin rather than for folding per se (see below). A variety of
other studies have shown that shortened connecting segments
donotpreventproinsulinfromfoldingproperlyandformingthe
correctdisulﬁdebondsofinsulin.Indeed,ithasbeensuggested
that directly linked single-chain B-A constructs completely de-
void of a connecting peptide can fold and be normally secreted
by neuroendocrine cells (Powell et al., 1988). However, more
recent studies have shown that such molecules have a strong
tendency to mispair disulﬁde bridges during folding (Liu et al.,
2003). They also are almost devoid of biological activity un-
less cleaved (Derewenda et al., 1991). A minimal C-peptide
chain length of several amino acids thus seems to be an es-
sential requirement for successful biosynthesis of the prohor-
mone. Even IGF1 with its shortened C domain of 11 residues
tendstopartiallyinterchangethedisulﬁdebridgesinvolvingthe
2adjacentcysteineresiduesatpositionsA6andA7undersome
conditions, but this misfolding event appears to be due mainly
to differences between the insulin and IGF B chain sequences
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AlthoughtheIGFshaveashorterthannormalCdomain,the
connecting peptide segment of prorelaxin, which gives rise to
relaxin, a more distant relative of insulin with a similar 2-chain
structure, is 104 residues in length in humans (Hudson et al.,
1984). Little is known regarding the proteolytic processing of
prorelaxin or its products, although it also appears likely to
involve members of the subtilisin-like prohormone convertase
family. The much greater length of the prorelaxin “C-peptide”
suggests the possibility that additional biologically active se-
quences may reside therein. Alternatively, it could merely re-
ﬂect (more faithfully than does proinsulin) the structure of
an ancestral insulin-like gene that might have arisen via exon
shufﬂing within a considerably larger protein (Steiner 1984).
In any case, the existence of prorelaxin, as well as 2 addi-
tional mammalian insulin-like peptides (Koman et al., 1996;
Burkhardt et al., 1994) shows that a much larger connecting
peptide segment than seen in proinsulin can also support cor-
rect folding of an insulin-like structure and this has also been
conﬁrmed experimentally by doubling the C-peptide in an ex-
pressed construct (Wei et al., 1995).
THE ROLES OF THE C-PEPTIDE IN INSULIN
BIOSYNTHESIS
Although the connecting segment clearly plays a key role in
insulinbiosynthesisbyensuringtheefﬁcientandcorrectpairing
of the A and B chains during the folding of proinsulin within
the cysternae of the endoplasmic reticulum as discussed above,
it also has a large number of additional constraints on its struc-
ture other than mere length. Mutations at selected sites in the
C-peptide in human proinsulin have been shown to inﬂuence
the refolding properties of the prohormone (Chen et al., 2002).
However, because it mainly functions as a ﬂexible connector to
convert insulin chain combination into a unimolecular, rather
than an otherwise bimolecular process, its structure also re-
ﬂects this role. Many of these structural constraints are listed
in Table 1 and will be brieﬂy considered below. Clearly, the
C-peptide must be removed from proinsulin to optimize the
biological activity of the mature insulin molecule and this re-
quires minimally the introduction of 4 basic amino acids, 2 at
either end, i.e., usually Arg-Arg at the B-chain junction and
Lys-Arg at the A-chain attachment site. To preserve overall
charge neutrality in the molecule then requires the presence of
4 or 5 acidic residues within the C-peptide and these are indeed
usually present (Figure 1). As a result, the isoelectric points of
proinsulin and insulin are closely similar (∼5.3). Interestingly,
deletions or alanine replacements of the acidic residues at po-
sitions 1, 3, and 4 of the human C-peptide impaired proinsulin
folding in vitro (Chen et al., 2002).
During folding, the C-peptide should be ﬂexible (the central
glycine-rich region ensures this) and must not interfere with
TABLE 1
Structural constraints on the C-peptide
• Length highly conserved—typically 31 residues (range
25–38)
• Maintains conservation of electrical charge in proinsulin
(pI ∼5.3)
• Promotes insulin assembly, but does not interact with B or
A chain domains
• Does not interfere with transport or sorting to secretory
granules
• Enhances interaction with convertases PC1/PC3 and PC2
for efﬁcient conversion to insulin
• Must be stable and compatible with other secretory granule
constituents, e.g., IAPP/amylin, others
• Must satisfy structural requirements for acquired
physiologic functions
the B or A chains during their folding interactions (evidence
suggests that all or most of the folding information is intrinsic
to theBandAchainsthemselves).Afactorthatmaycontribute
to the “inertness” of the C-peptide is the absence of any aro-
matic residues (Tyr, Phe, or Trp). However, 4 tyrosines and
3 phenylalanines are present in the insulin molecule and it is
likely that C-peptide contacts with these must be avoided dur-
ing folding (Weiss et al., 1990). There is no space available
for the C-peptide in the compactly folded insulin structure and,
thus, after folding, it remains outside the insulin moiety as a
large unstructured loop. It also does not prevent the self asso-
ciation of proinsulin into dimers and zinc-stabilized hexamers
(Blundell et al., 1972; Brems et al., 1990). Indeed, the 6 largely
unorderedC-peptideloopsremain“outside”thesphericalstruc-
ture formed by the 6 densely packed insulin moieties in proin-
sulin hexamers, somewhat resembling the serpents on a mythi-
cal Medusa’s head, and serving to block the premature packing
of proinsulin hexamers into the crystalline insulin arrays that
makeupthetypicaldensegranuleinclusionsastheseformdur-
ing secretory granule maturation (Steiner, 1973; Michael et al.,
1987).
The C-peptide must also support the sorting of proinsulin
into the dense core granules as these are formed and it should
not interfere with the processing or storage of any of the other
granule components. The C-peptide may in fact play a role in
stabilizing secretory granules, as it is retained in the soluble
phase in the granules where it may interact with and/or stabi-
lize other secretory products such as islet amyloid polypeptide
(IAPP or amylin). It has been reported to retard aggregation of
human IAPP into amyloid ﬁbrils in vitro (Westermark et al.,
1996). Because there are a large number of soluble molecules,
including peptides, nucleotides, amino acids, and ions, withinPROINSULIN C-PEPTIDE 11
FIGURE 2
Normal two-step pathway for the conversion of proinsulin to insulin, based on conformational modeling of the optimal
orientations of the cleavage sites (space-ﬁlling residues) for interaction with the prohormone convertases during proinsulin
processing (upper left panel). Note the extended C-peptide conﬁguration (blue ribbon), which permits the wide separation of the
C-end of the B chain (yellow ribbon) from the N-end of the A chain (magenta ribbon), allowing cleavage ﬁrst after R32 by PC1/3
(arrow, upper left panel) and then after R65 by PC2 (arrow, lower left panel). To allow cleavage of the C-peptide–A chain
junction, the N-terminal helix of the A chain must partly unwind to allow I67 to occupy the S2  subsite of PC2, as indicated in the
left panels. After cleavage, I67 resumes its normal position in the hydrophobic core of insulin now designated I A2 (lower right
panel)( R= arginine; I = isoleucine). (For further modeling details, see Lipkind, 1999.)
the secretory granules, the C-peptide clearly must maintain
compatibility with this environment.
Finally, and perhaps most importantly, the C-peptide must
facilitate its own excision from proinsulin during the matura-
tion to insulin. Modeling studies have indicated that the length
and ﬂexibility of the C-peptide also contributes importantly
in this regard as well (Figure 2). At least 8 or 9 residues
(6upstreamand2or3downstream)atthe2proinsulinprocess-
ingsitesmustﬁtintothecatalyticgroovesontheconvertasesas
extended β strands in order for cleavage to occur (Lipkind and
Steiner, 1999). This is more easily accomplished at the B-chain
junction, which is highly ﬂexible and can easily assume such
a conﬁguration for interaction with PC1/3, assisted by the con-
siderable length and ﬂexibility of the C-peptide and the ﬂexible
C-terminal B-chain segment, which is not integral to the folded
insulin structure. However, this is more difﬁcult at the A-chain
junction where residues A1–A3 are part of an N-terminal alpha
helix and the A2-isoleucine side chain is in close contact with
the tyrosine side chain of A19 within the hydrophobic core of
the insulin moiety (Weiss et al., 1990). Hence, this helix must
partially unwind, allowing the A2 isoleucine to move out of
the insulin core and occupy the S2  site of the catalytic groove
of PC2 (Lipkind and Steiner, 1999). The extended C-peptide,
especiallyafterbeingfreedfromitsB-chainattachmentbyprior
cleavage of this site by PC1/3 (Zhu et al., 2002), may be able
to exert sufﬁcient traction on the A-chain helix to assist this
structural transition, which allows PC2 to complete the con-
version process. After cleavage and dissociation from PC2, the
insulin A-chain helix will spontaneously reform, allowing the
A2isoleucinetoreestablishitsinternalcontactwithintheinsulin12 D. F. STEINER
molecule. Thus, here again, in this critical process, we see that
the C-peptide length plays both an active as well as a passive
role.
BIOLOGICAL ACTIONS OF C-PEPTIDE
Surely the very high degree of conservation of an overall
lengthintheC-peptideofabout30residues,aswellastheother
structural considerations discussed above, provide an adequate
functional framework to account for the degree of evolutionary
conservation seen in the C-peptide. This region of proinsulin
accepts mutations at a rate that is 12 to 15 times faster than
the rate of evolutionary change in insulin, which is constrained
not only by its own receptor-binding requirements, but those
of maintaining a clear-cut duality of recognition to differenti-
ate it from its sibling molecules, especially the closely related
IGFs. On this basis, it is tempting to conclude that were the
C-peptide additionally constrained by requirements for inter-
acting with a receptor of its own, we might see some higher
degree of conservation of structure somewhere within the C-
peptides, but this does not appear to be the case, as the variabil-
ity extends throughout the molecule. Nonetheless, a number of
physiological functions of the C-peptide, ranging from stimu-
lation of sodium-potassium ATPase activity, altered neural and
vascular function, to even some insulin-like actions, have been
described in recent years (Wahren et al., 1994; Kitamura et al.,
2001; Ido et al., 1997) or are discussed in articles included in
this volume. A putative C-peptide receptor has also been iden-
tiﬁed, but has not yet been isolated or characterized (Rigler
et al., 1999; Henriksson et al., 2001). It will be of great interest
to learn more about this receptor molecule and its recognition
properties. It is unlikely that C-peptide interacts directly with
lipid membranes (Henriksson et al., 2000). However, it should
be borne in mind that peptides can be taken up by cells via en-
docytosis or possibly also pinocytosis, and could exert actions
within cells that might not require conservation of structure be-
yondthatseeninthemammalianC-peptides.Itcertainlyseems
likelythattheC-peptidemaybeastructurethathasacquiredad-
ditional physiological functions during mammalian evolution.
Indeed, the C-peptide is a fascinating entity, beginning with its
original vital role in ensuring the synthesis and correct assem-
bly of the insulin molecule, but perhaps also going beyond that
role to assume further important endocrine functions of its own
by virtue of its temporal association with insulin in the ebb and
ﬂow of metabolism over the eons.
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